Option chain shows key data for Matinas BioPharma Hldgs's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Matinas BioPharma Hldgs.

Matinas BioPharma Hldgs (AMEX:MTNB) Stock, Option Chain

Matinas BioPharma Hldgs

Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.

xr:d:DAFfORZ4lNo:2,j:2185570849,t:23040509

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

BJDX

BURU

CLDI

CYCC

DBGI

EFSH

ELAB

HROW

IBTA

MTNB

QBTS

QUBT

SMCI

SVMH

TSHA

XTIA

ZCAR

ZETA

Why DLocal Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket

BAER

BNOX

BTCT

CERO

DXYZ

GRAB

LAZR

LGMK

LIFW

Eaton Vance Massachusetts Municipal Income Trust

NGNE

OGEN

TAOP

Why Grab Holdings Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket

Uber stock

Earnings

Equities

Eurozone

Commodities

Intraday Update

ATEC

CMPS

LMND

ROOT

UBER

Nasdaq Down 500 Points; Uber Shares Dip After Q3 Results

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Holdings Inc

Press Releases

New In Vitro Data Showing Matinas BioPharma's LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024

Health Care

Matinas BioPharma's Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin

Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program

Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024

Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update

Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction

Matinas BioPharma Receives NYSE Noncompliance Notice

111 Equity Group increases stake in Matinas Biopharma Holdings, Inc.

Management

Matinas BioPharma Appoints Evelyn D'An to Board of Directors as Audit Committee Chair

Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

Bone Biologics

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

Entero Therapeutics

Genprex

Lipella Pharmaceuticals Inc. - Common Stock

Lipella Pharmaceuticals

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

NuCana

Oragenics

Onconetix

Palisade Bio

Polyrizon

Plus Therapeutics

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals

Synaptogenix

Syros Pharmaceuticals, Inc. - Common Stock

Syros Pharmaceuticals

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics

Tharimmune

Theriva Biologics

Windtree Therapeutics, Inc. - Common Stock

Windtree Therapeutics

ZyVersa Therapeutics, Inc. - Common Stock

ZyVersa Therapeutics

BTIG

HC Wainwright & Co.

Comments

Matinas BioPharma Hldgs

Matinas BioPharma Hldgs (MTNB) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga